Hepatocellular carcinoma (HCC) is increasingly recognized as a major global health issue, with rising incidence and mortality rates, particularly in the United States.

Key contributors to the development of HCC include chronic viral hepatitis, non-alcoholic steatohepatitis (NASH), and excessive alcohol consumption.

Despite existing treatment options such as liver resection and transplantation, the aggressive nature of HCC results in poor survival rates, underscoring the urgent need for improved understanding and interventions.

The Notch signaling pathway plays a crucial role in cell differentiation and proliferation, with its effects on tumor progression varying based on the tumor microenvironment.

Recent research has explored the relationship between UBE2C expression and clinical outcomes in HCC, highlighting UBE2C's involvement in regulating the Notch pathway and suggesting its potential as a therapeutic target.

In addition to its regulatory role, UBE2C has been shown to facilitate cell migration and invasion, with in vivo studies indicating that silencing UBE2C leads to reduced pulmonary metastasis.

Analysis of tissue samples from HCC patients revealed that UBE2C is highly expressed in cancerous tissues compared to adjacent noncancerous tissues.